The SMAC mimetic, LCL-161, reduces survival in aggressive MYC-driven lymphoma while promoting susceptibility to endotoxic shock
Alison C. West(Hudson Institute), Jake Shortt(The University of Melbourne)
Cited by 32
Related Papers
New and emerging HDAC inhibitors for cancer treatment
|Journal of Clinical Investigation|2014|1.4k
Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition
|Molecular Cell|2021|167
Rationally designed chimeric PI3K-BET bromodomain inhibitors elicit curative responses in MYC-driven lymphoma
|Proceedings of the National Academy of Sciences|2023|9